Gelteq Limited Ordinary Shares (GELS) - Total Liabilities
Based on the latest financial reports, Gelteq Limited Ordinary Shares (GELS) has total liabilities worth $5.67 Million USD as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Gelteq Limited Ordinary Shares - Total Liabilities Trend (2020–2025)
This chart illustrates how Gelteq Limited Ordinary Shares's total liabilities have evolved over time, based on quarterly financial data. See GELS working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Gelteq Limited Ordinary Shares Competitors by Total Liabilities
The table below lists competitors of Gelteq Limited Ordinary Shares ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Buff Technologies Ltd
TA:BUFT
|
Israel | ILA4.66 Million |
|
Throgmorton Trust Plc
LSE:THRG
|
UK | GBX6.49 Million |
|
333D Ltd
AU:T3D
|
Australia | AU$385.73K |
|
Quantum Genomics SA
PA:ALQGC
|
France | €2.81 Million |
|
Hansa Investment Company Ltd
LSE:HANA
|
UK | GBX1.42 Million |
|
SIV Capital Ltd
AU:SIV
|
Australia | AU$113.58K |
|
Harworth Group PLC
LSE:HWG
|
UK | GBX358.73 Million |
Liability Composition Analysis (2020–2025)
This chart breaks down Gelteq Limited Ordinary Shares's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Gelteq Limited Ordinary Shares stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.27 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.36 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.26 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Gelteq Limited Ordinary Shares's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Gelteq Limited Ordinary Shares (2020–2025)
The table below shows the annual total liabilities of Gelteq Limited Ordinary Shares from 2020 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | $5.67 Million | +0.45% |
| 2024-06-30 | $5.65 Million | +47.17% |
| 2023-06-30 | $3.84 Million | +50.24% |
| 2022-06-30 | $2.55 Million | +533.24% |
| 2021-06-30 | $403.23K | +1.81% |
| 2020-06-30 | $396.04K | -- |
About Gelteq Limited Ordinary Shares
Gelteq Limited focuses on developing and commercializing white label gel-based delivery solutions for humans and animals in the United States of America and Australia. It offers edible gels for prescription drugs, nutraceuticals, pet care, and other products, as well as for sports and over-the-counter products. Gelteq Limited was incorporated in 2017 and is headquartered in Clayton, Australia.